[{"data":1,"prerenderedAt":494},["ShallowReactive",2],{"story-208987-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":79,"questions":80,"relatedArticles":102,"body_color":492,"card_color":493},"208987",null,"Pharmaceutical False Advertising Precedent | Lanham Act Enforcement Tightens for Health Product Sellers","- Novo's July 2025 lawsuit establishes stricter comparative claim standards; affects 50K+ health supplement sellers using clinical data in ads",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,22,23,24,25,26,27,28,29,30,31,32,27,33,34,35,36,37,16,38,39,40,41,42,16,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,58,17,42,67,68,61,69,70,71,72,73,65,74,75,76,77,78],"https://www.statnews.com/wp-content/uploads/2026/07/GettyImages-2281096688-645x645.jpg","https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg","https://assets.medpagetoday.net/media/images/122xxx/122290.jpg?width=0.8","https://images.wsj.net/im-55442761?width=700&height=466","https://www.raps.org/static/a590c465-cdda-4276-b84d93c9cb2fe4ac/440x248_highestperformance__4a7c7e45a350/RegulatoryRecon440x248.jpg","https://cdn.sanity.io/images/0vv8moc6/pharma_commerce/51fd9b328adf2f2e73673ce7a0579fc1376748e6-3840x2160.jpg","https://imgproxy.divecdn.com/4jSQwpCLqm7YrbEDTGT_wAXx2xuTdUBAJCJE03wWNsk/g:nowe:0:388/c:5567:3145/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgxMDU3NjQ0LmpwZw==.webp","https://biz.chosun.com/resizer/v2/GFSDOZBQMEYTMNBQMM2TINJTGI.jpg?auth=aa3b4450df01a0ac69d0c51dd1ee7195b0ee2b400fc8942bf5a96f94aa5e48e4&width=700&height=367&smart=true","https://th.bing.com/th?id=OMSN.AA28oWdA.webp-.5U&pid=wdpv2&w=1000&h=1000&qlt=90&c=1&rs=1","https://images.mktw.net/im-72153366?width=1260&height=840","https://ca-times.brightspotcdn.com/dims4/default/4f7de08/2147483647/strip/true/crop/2000x1050+0+142/resize/1200x630!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F33%2F4a%2Fb6c70cfb5e33230000f4e7f2eb71%2F1x-1.jpg","https://ichef.bbci.co.uk/ace/standard/1024/cpsprodpb/8c4c/live/b65dcff0-8508-11f1-bee8-53ce494e1abc.jpg","https://assets3.cbsnewsstatic.com/hub/i/r/2026/07/01/0ecd33c4-5c1b-49ef-a457-d23c1d961e08/thumbnail/1200x630/919355e532ad5614dde5561beecf4c72/cbsn-fusion-what-to-know-about-medicare-covering-glp-1-drugs-thumbnail.jpg","https://www.livemint.com/lm-img/img/2026/07/21/1600x900/logo/Obesity-Pill-Knockoff-0_1770373926962_1770373947646_1784634966674_26135417-ca40-4ebe-9280-feda6e9bd8ae.jpg","https://i.guim.co.uk/img/media/39b7491497130e6f0926d45f7bb2cd3260c276ca/0_0_1200_960/master/1200.jpg?width=465&dpr=1&s=none&crop=none","https://image.cnbcfm.com/api/v1/image/108328219-1782751789876-gettyimages-2279484892-64393_48_ms_4772.jpeg?v=1782751835&w=1600&h=900","https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1549769756-750x406.jpg","https://thehill.com/wp-content/uploads/sites/2/2025/11/AP25183580105195-e1762524242816.jpg?strip=1","https://cdn.newser.com/image/1700044-11-20260721103918-novo-nordisk-eli-lilly-lying-weight-loss-ads.jpeg","https://manufacturingchemist.com/novo-nordisk-sues-eli-lilly-over.png","https://cdn.ibj.com/wp-content/uploads/2025/05/Injectibles-ozempic-wegovy-mounjaro-e1747931193557.jpg","https://imageio.forbes.com/specials-images/imageserve/6a5f6ca464812181fb5dfcef/photo-illustration-of-a-group-of-weight-loss-injection-pen-medications-/0x0.jpg?crop=5400,3038,x0,y333,safe&height=400&width=711&fit=bounds","https://cached.imagescaler.hbpl.co.uk/resize/scaleWidth/1272/cached.offlinehbpl.hbpl.co.uk/news/ORP/GettyImages-2252640387.jpg","https://ichef.bbci.co.uk/news/480/cpsprodpb/8c4c/live/b65dcff0-8508-11f1-bee8-53ce494e1abc.jpg.webp","https://biostock.se/wp-content/uploads/2026/03/usa.webp","https://images.barrons.com/im-46985947?width=700&height=466","https://static.foxbusiness.com/foxbusiness.com/content/uploads/2026/07/ozempic-pen-shot.jpg","https://www.barrons.com/asset/external-media/afp/AFP1111745118122615364731718859570615496836---1.jpg","https://s.yimg.com/lo/mysterio/api/b1f339b9b574508ee1de54da8e5c614909f5205a489cdf8d24f5a43cb1f3334a/lightyear_networkapi/resizefill_w1200;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fwish_tv_176%2Fa6fceb90b45abe913a9187f7324308b0","https://cphoto.asiae.co.kr/listimglink/1/2026072209324653669_1784680365.jpg","https://assets.qz.com/media/GettyImages-2252640101-1920x1280.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w630","https://live.euronext.com/sites/default/files/2026-07/12900029_2.jpg?VersionId=emNdQedzxCJMzsVAFp9mmLVrDp3lOk3y","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iAFSWhL4XlyA/v3/400x225.jpg","https://www.reuters.com/resizer/v2/N7RRZI6T2JJRJED4IOLM2FH35I.jpg?auth=35358b46ba8276b0d7dec0a4153cfdff1abc7e7495f989880df6c88a47ec0129&width=1080&quality=80","https://img.ksl.com/slc/3195/319516/31951696.JPG?filter=kslv2/responsive_story_lg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iSHg5DGzv7zU/v0/-1x-1.webp","https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/113852b6-0096-42ce-bbe3-fe3f5ae005d7/main/1280x720/46s954ms/match/image.jpg","https://cdn.sanity.io/images/0vv8moc6/pharmtech/ddba3b2e74ef4fde464458f0f0483be8d238c453-1280x731.gif","https://images.axios.com/_sp9UQSX_0lA2ZSrf8fk5-WOJ64=/2025/02/10/201653-1739218613760.jpg","https://media-cldnry.s-nbcnews.com/image/upload/t_nbcnews-fp-1024-512,f_auto,q_auto:best/rockcms/2026-03/260310-Novo-Nordisk-ew-442p-ff02e0.jpg","https://s.yimg.com/lo/mysterio/api/D1468B80F602791455BFF7D9D4D0A11DE525009796EB44F0E18323E82A425C5E/subgraphmysterio/resizefit_w960;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fproactive_us_504%2Fa5b561ce9ae1fa1c48b4be65a06bdea7","https://pharmaphorum.com/sites/default/files/styles/x_large/public/2024-11/wesley-tingey-plaintiff-unsplash.jpg?itok=-_XTu0Rr","https://news.stocktwits-cdn.com/large_Novo_Nordisk_jpg_96dd19f953.webp","https://blog.tipranks.com/wp-content/uploads/2026/07/aaa-119-750x406.jpg","https://d29szjachogqwa.cloudfront.net/images/user-uploaded/eb5204e1-76dd-47c2-9b42-6f039bd619ed_0950525e0a28e7b4d105fe5b6ba6e4bcd7e354fdf9c79b53a1f5a853b9393de9.jpg","https://cdn.thepharmaletter.com/files/2024/06/97b90240-22a4-11ef-aa19-3f6c55186234-novo-nordisk-large.jpg","https://news-api.bloomberglaw.com/v1/resize-image?url=https%3A%2F%2Fbloomberg-bna-brightspot.s3.us-east-1.amazonaws.com%2F17%2F18%2F9ead0b4945ebbefc59527057c4b7%2Fzepbound.jpg&width=1240&height=480&fit=cover&crop=3994x1539%2B3%2B734","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://cdn.jwplayer.com/v2/media/edhBLngn/poster.jpg?width=720","https://media.zenfs.com/en/simply_wall_st__316/9bd772b568bf21790e1e1f0fdd05b70b","https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2Fb82b90f08bf192e4b772d340e850e0aeb2fc7486-2000x1200.jpg%3Fw%3D2000%26h%3D1200%26q%3D75%26auto%3Dformat&w=3840&op=resize","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/19488285/7vnfpf/ALTERNATES/master-3_2/health-obesityusa","https://img-cdn.inc.com/image/upload/f_webp,q_auto,c_fit/vip/2026/07/eli-lilly-lawsuit-inc-1536779881.jpg","https://s.yimg.com/lo/mysterio/api/02AE8D2450002B79B3F7187A8C2D907F11DE3F272F9F1886A59AE4E9C3D368C8/subgraphmysterio/resizefill_w1200_h675;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2F9f505d3082c5c32dd86790426e65a15d","https://ewscripps.brightspotcdn.com/dims4/default/a46154d/2147483647/strip/true/crop/1024x538+0+73/resize/1200x630!/quality/90/?url=https%3A%2F%2Fewscripps.brightspotcdn.com%2Ff8%2F0e%2Fe7df02c342c2af14aab264f9b0bc%2Fap25310565797719.jpg","https://www.reuters.com/resizer/v2/VIUDCD2I55PBXJYDNJUS2UDDE4.jpg?auth=44f23262606fedbf9b72c3e04322b38c14d0ec9619aaf79f3e4b81f87f54a9f7&height=2400&width=1920&quality=80&smart=true","https://s.yimg.com/lo/mysterio/api/1e52df570e9289e26ff430280e83bf4d5967877b0df0244a2ae037ba1fb860b6/lightyear_networkapi/resizefill_w1200;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fnbcu_713%2F3c1086438cb93254a6b774026afab379","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/business_novo_lilly_rivalry.jpeg","https://images.wsj.net/im-925349/social","https://static.dw.com/image/75277465_804.jpg","https://menafn.com/updates/pr/2026-07/21/TP_48d71image_story.jpg","https://s.yimg.com/lo/mysterio/api/C985878170623B3E92B1ADFF0D3FE6100C6978B5660C79969AEF867FBC11734A/subgraphmysterio/resizefit_w960;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fafp.com%2F65c8c6d124239db099c7d03c82220755","https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/ozempic.jpg?VersionId=o92XoiXw_H_eKMoXxUNTbjkqMi0i2bwM","https://schaeffers-cdn.s3.amazonaws.com/images/default-source/schaeffers-cdn-images/default-images/investor/bigstock-stock-market-or-forex-trading--369802987.jpg?sfvrsn=fde8db06_4","https://www.devdiscourse.com/img?imageUrl=https://devdiscourse.blob.core.windows.net/aiimagegallery/01_10_2025_03_49_05_0814214.png&width=1280","https://media11.s-nbcnews.com/i/mpx/2704722219/2026_07/1784636244959_tdy_news_8a_romans_novo_nordisk_lawsuit_260721_S3_1920x1080-chybuj.jpg","https://www.reuters.com/resizer/v2/VIUDCD2I55PBXJYDNJUS2UDDE4.jpg?auth=44f23262606fedbf9b72c3e04322b38c14d0ec9619aaf79f3e4b81f87f54a9f7&width=1080&quality=80","**Novo Nordisk's landmark false advertising lawsuit against Eli Lilly (filed July 21, 2025, U.S. District Court, New Jersey) establishes critical precedent for how pharmaceutical and health product companies can present comparative efficacy claims in consumer-facing advertising.** The case centers on Lilly's Zepbound television commercials claiming 50 pounds of weight loss versus Novo's Wegovy at 33 pounds—comparisons based on outdated clinical trial data from 2024 that compared Zepbound's highest dose (10-15 mg) against Wegovy's lower dose (1.7-2.4 mg). Novo argues this is materially misleading because the FDA approved Wegovy's 7.2 mg dose in March 2025, with separate trials showing comparable results (47 pounds vs. Zepbound's 48 pounds at maximum doses). Lilly's modified ad campaign generated over 700 million impressions since April 2025 before the lawsuit.\n\n**The regulatory and competitive implications are substantial for e-commerce sellers in health categories.** Novo invokes the **Lanham Act** for federal unfair competition and false advertising claims, arguing that consumers rely on advertising rather than healthcare professional guidance when evaluating GLP-1 treatment options. This legal theory directly applies to Amazon, Shopify, and other platforms where health supplement sellers make comparative efficacy claims. The lawsuit signals that regulatory enforcement will scrutinize: (1) whether comparative data is current and head-to-head at equivalent doses, (2) whether disclaimers about excluded data are sufficiently prominent (Novo alleges Lilly's footnotes are \"small and illegible\"), and (3) whether sellers selectively present outdated studies to inflate competitive advantage. The U.S. obesity drug market exceeds $100 billion by 2030 projections, making this a high-stakes battleground where marketing claims directly influence consumer purchasing decisions.\n\n**For cross-border health product sellers, this case creates immediate compliance obligations.** Sellers marketing weight-loss supplements, diabetes management products, or any health category using comparative clinical claims must now: (1) ensure all cited trial data is current and reflects highest approved/available doses, (2) make disclaimers about excluded data clearly visible (not in small footnotes), (3) avoid selective presentation of outdated studies, and (4) maintain documentation proving comparative claims are head-to-head trials at equivalent dosages. The Lanham Act provides for injunctive relief (ad removal), corrective advertising campaigns, and damages including defendant's profits attributable to false ads—creating significant financial exposure. Lilly's defense (that head-to-head trials are the \"gold standard\" and that it discloses exclusions) may not succeed if courts find the disclosure insufficient or the comparison fundamentally misleading. This precedent will influence how Amazon, eBay, Shopify, and TikTok Shop enforce health product advertising policies, likely requiring sellers to submit clinical documentation before approving comparative claims.",[81,84,87,90,93,96,99],{"title":82,"answer":83,"author":5,"avatar":5,"time":5},"What disclaimer standards must health product sellers follow after this lawsuit?","Novo's lawsuit specifically alleges that Lilly's disclaimers about excluded data are 'small and illegible,' suggesting courts will scrutinize disclaimer prominence and placement. For sellers, this means: (1) disclaimers must be clearly visible and readable (not in fine print or footnotes), (2) disclaimers must explicitly state what data is excluded and why (e.g., 'comparison excludes Competitor's highest-dose formulation approved March 2025'), (3) disclaimers cannot be buried in video captions or end-of-ad text, and (4) sellers must maintain documentation proving all comparative claims are supported by current, equivalent-dose trials. The FTC's Endorsement Guides (16 CFR Part 255) already require clear and conspicuous disclosures, but this case raises the bar for health product categories specifically.",{"title":85,"answer":86,"author":5,"avatar":5,"time":5},"How will this lawsuit affect health product sellers' ability to use clinical trial data in advertising?","The Novo v. Lilly precedent establishes that sellers must: (1) use only current clinical trial data (not studies completed 12+ months ago if newer data exists), (2) ensure trials are head-to-head comparisons at equivalent doses, (3) disclose all relevant trial results, not selectively present favorable data, and (4) update advertising immediately when new FDA approvals or clinical data become available. Sellers cannot rely on older trials if newer, higher-dose formulations have been approved. This significantly restricts the marketing flexibility sellers previously enjoyed. For example, a supplement seller claiming superiority over a competitor must now conduct or cite current head-to-head trials at equivalent dosages, not rely on 2-3 year old studies. Non-compliance risks FTC enforcement, platform removal, and private litigation under the Lanham Act.",{"title":88,"answer":89,"author":5,"avatar":5,"time":5},"What specific advertising claims does Novo argue are false in Lilly's Zepbound commercials?","Novo contends that Lilly's television ads claim Zepbound achieves 50 pounds of weight loss versus Wegovy's 33 pounds, but this comparison relies on outdated 2024 clinical trial data comparing Zepbound's highest dose (10-15 mg) against Wegovy's lower dose (1.7-2.4 mg). The FDA approved Wegovy's 7.2 mg dose in March 2025, and separate trials show Wegovy at maximum dose achieves 47 pounds of weight loss—nearly equivalent to Zepbound's 48 pounds. Novo argues no head-to-head trial currently compares the highest approved doses of both drugs, making Lilly's comparative efficacy claims unfounded and materially misleading to consumers who rely on advertising rather than healthcare professional guidance.",{"title":91,"answer":92,"author":5,"avatar":5,"time":5},"How does the Lanham Act apply to health supplement sellers on Amazon and Shopify?","The Lanham Act (15 U.S.C. § 1125) prohibits false or misleading advertising in commerce, including comparative claims about product efficacy. For health supplement sellers, this means any comparative claims (e.g., 'our weight-loss formula outperforms Brand X by 30%') must be supported by current, head-to-head clinical trials at equivalent dosages. Sellers cannot selectively present outdated studies or compare their highest dose against competitors' lower doses. Violations expose sellers to injunctive relief (ad removal), corrective advertising campaigns, and damages including profits attributable to false ads. Amazon and Shopify increasingly require clinical documentation before approving comparative health claims, and the Novo v. Lilly precedent will likely tighten these policies further.",{"title":94,"answer":95,"author":5,"avatar":5,"time":5},"What is the timeline for this lawsuit and when might sellers see regulatory changes?","Novo filed the lawsuit on July 21, 2025, in U.S. District Court for the District of New Jersey. Novo plans to pursue a preliminary injunction if Lilly refuses voluntary compliance, which could result in ad removal within weeks to months. A preliminary injunction decision could come within 3-6 months, establishing interim precedent for advertising standards. Full litigation could take 1-3 years, but the preliminary injunction phase will likely influence platform policies sooner. Sellers should expect Amazon, Shopify, and eBay to tighten health product advertising policies within 6-12 months based on this case. Immediate actions: audit all comparative claims, document clinical trial sources, update disclaimers, and consult legal counsel on compliance. Sellers should also monitor FTC enforcement actions and platform policy updates for changes to health product advertising standards.",{"title":97,"answer":98,"author":5,"avatar":5,"time":5},"What are the financial penalties and remedies Novo seeks in this lawsuit?","Novo seeks: (1) a permanent injunction requiring Lilly to withdraw all misleading advertisements, (2) corrective advertising campaigns (Lilly must fund ads correcting the false claims), and (3) unspecified financial damages including Lilly's profits attributable to the false ads. Lilly's Zepbound commercial generated over 700 million impressions since April 2025, suggesting damages could reach tens to hundreds of millions of dollars if courts find the ads materially misleading. For health product sellers, this demonstrates the financial exposure of false advertising claims. Even small sellers with $1-5M annual revenue could face damages exceeding annual profits if comparative claims are found false. This incentivizes sellers to invest in current clinical documentation and conservative advertising claims.",{"title":100,"answer":101,"author":5,"avatar":5,"time":5},"How does this lawsuit affect sellers marketing weight-loss supplements on Amazon, eBay, and Shopify?","Weight-loss supplement sellers must now assume stricter scrutiny of comparative efficacy claims. Amazon Seller Central, eBay, and Shopify are likely to: (1) require clinical trial documentation before approving comparative claims, (2) flag listings using outdated trial data, (3) enforce stricter disclaimer requirements, and (4) remove listings making unsupported comparative claims. Sellers should audit all product listings and advertising copy for comparative claims, verify that cited trials are current and head-to-head at equivalent doses, and add prominent disclaimers about excluded data. The $100 billion+ obesity drug market creates high-stakes competition, and platforms will enforce compliance more aggressively to avoid liability. Sellers in this category should budget for legal review of advertising claims and consider obtaining E&O insurance covering false advertising liability.",[103,108,113,117,121,125,129,133,136,140,144,148,152,156,160,164,168,172,176,180,184,188,192,196,200,204,208,212,216,220,224,228,232,236,240,244,248,252,256,259,263,267,270,274,278,282,286,290,294,297,301,305,309,313,316,320,324,328,331,335,338,342,345,349,353,356,359,362,365,369,373,376,380,384,388,392,396,401,404,408,411,415,418,422,426,430,433,437,441,444,448,452,456,459,462,466,470,473,476,480,484,488],{"id":104,"title":105,"source":106,"logo":16,"time":107},1278670,"Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs","https://www.healthcaredive.com/news/novo-lilly-lawsuit-obesity-drug-glp1-marketing/825801","2D AGO",{"id":109,"title":110,"source":111,"logo":60,"time":112},1278671,"Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings","https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-stock-looks-041501100.html","4D AGO",{"id":114,"title":115,"source":116,"logo":17,"time":107},1278672,"Novo Nordisk sues Eli Lilly over Mounjaro–Wegovy ad claims - CHOSUNBIZ","https://biz.chosun.com/en/en-science/2026/07/22/4VCKIY7VM5DLJF6OBSWUTNK3NM",{"id":118,"title":119,"source":120,"logo":65,"time":107},1278677,"Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false'","https://www.10news.com/business/company-news/novo-nordisk-sues-eli-lilly-alleging-the-companys-glp-1-ads-are-deliberately-false",{"id":122,"title":123,"source":124,"logo":38,"time":107},1278673,"Novo Nordisk sues Lilly over advertising","https://www.yahoo.com/news/videos/novo-nordisk-sues-lilly-over-213938577.html",{"id":126,"title":127,"source":128,"logo":18,"time":107},1278674,"Novo Nordisk sues Eli Lilly over weight-loss drug ad claims","https://www.msn.com/en-us/news/insight/novo-nordisk-sues-eli-lilly-over-weight-loss-drug-ad-claims/gm-GM8D3F3719?gemSnapshotKey=GM8D3F3719-snapshot-4&uxmode=ruby&cvid=6a5fdcb4c66848aa817a174036e0e528",{"id":130,"title":131,"source":132,"logo":5,"time":107},1278675,"Novo Nordisk sues Eli Lilly, alleges deceptive advertising for Zepbound","https://www.wishtv.com/news/business/novo-nordisk-sues-eli-lilly-alleges-deceptive-advertising-for-zepbound",{"id":134,"title":119,"source":135,"logo":65,"time":107},1278676,"https://www.news5cleveland.com/business/company-news/novo-nordisk-sues-eli-lilly-alleging-the-companys-glp-1-ads-are-deliberately-false",{"id":137,"title":138,"source":139,"logo":78,"time":107},1275222,"Novo sues Lilly, claiming misleading ads in weight-loss drug battle","https://www.reuters.com/world/novo-nordisk-says-it-is-suing-eli-lilly-accusing-it-false-advertising-2026-07-21",{"id":141,"title":142,"source":143,"logo":50,"time":107},1275226,"Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising","https://www.nbcnews.com/business/business-news/novo-nordisk-says-suing-eli-lilly-accusing-false-advertising-rcna588513",{"id":145,"title":146,"source":147,"logo":13,"time":107},1275225,"Novo Sues Rival Lilly Over Alleged False Advertising in Weight-Loss Ads","https://www.wsj.com/health/pharma/novo-nordisk-files-deceptive-advertising-lawsuit-against-rival-eli-lilly-2579eb2b",{"id":149,"title":150,"source":151,"logo":30,"time":107},1275224,"Novo Nordisk sues Eli Lilly over ‘misleading’ GLP-1 advertisements","https://www.ibj.com/articles/novo-nordisk-sues-eli-lilly-over-misleading-glp-1-advertisements",{"id":153,"title":154,"source":155,"logo":25,"time":107},1275223,"Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising","https://www.cnbc.com/2026/07/21/novo-nordisk-sues-eli-lilly-glp-1-ads.html",{"id":157,"title":158,"source":159,"logo":22,"time":107},1275229,"Novo Nordisk sues Eli Lilly over \"maliciously and deceptively false\" GLP-1 ads","https://www.cbsnews.com/news/novo-nordisk-eli-lilly-false-advertising-lawsuit",{"id":161,"title":162,"source":163,"logo":33,"time":107},1275228,"Ozempic-maker Novo Nordisk sues rival Eli Lilly, accusing it of false advertising","https://www.bbc.com/news/articles/c3v0rzd2l17o",{"id":165,"title":166,"source":167,"logo":46,"time":107},1275227,"Novo Nordisk Says It’s Suing Eli Lilly Over Weight-Loss Ads","https://www.bloomberg.com/news/articles/2026-07-21/novo-nordisk-says-it-s-suing-eli-lilly-over-weight-loss-ads",{"id":169,"title":170,"source":171,"logo":74,"time":107},1275233,"Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads","https://www.fiercepharma.com/marketing/novo-accuses-lilly-running-false-and-misleading-glp-1-ads",{"id":173,"title":174,"source":175,"logo":31,"time":107},1275232,"Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising","https://www.forbes.com/sites/conormurray/2026/07/21/novo-nordisk-sues-glp-1-rival-eli-lilly-for-misleading-advertising",{"id":177,"title":178,"source":179,"logo":11,"time":107},1275231,"Pharmalittle: We're reading about Novo suing Lilly over 'deceptive' ads, a fugitive's secret life in biotech, and more","https://www.statnews.com/pharmalot/2026/07/21/novo-sues-lilly-alleging-deceptive-ads-fugitive-secret-life-in-biotech",{"id":181,"title":182,"source":183,"logo":20,"time":107},1275230,"Weight-loss drug wars escalate as Novo Nordisk targets Eli Lilly ads in lawsuit","https://www.latimes.com/business/story/2026-07-21/weight-loss-drug-wars-escalate-as-novo-nordisk-targets-eli-lilly-ads-in-lawsuit",{"id":185,"title":186,"source":187,"logo":5,"time":107},1275237,"Novo Nordisk sues Eli Lilly over 'deliberately false' GLP-1 ads","https://www.usatoday.com/story/money/2026/07/21/wegovy-maker-novo-sues-rival-eli-lilly-weight-loss-drugs/90985399007",{"id":189,"title":190,"source":191,"logo":77,"time":107},1275236,"Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Advertisement","https://www.today.com/video/novo-nordisk-sues-eli-lilly-over-weight-loss-drug-advertisement-267010117600",{"id":193,"title":194,"source":195,"logo":37,"time":107},1275235,"Pharma Heavyweights Clash Over Anti-obesity Drug Ads","https://www.barrons.com/news/pharma-heavyweights-clash-over-anti-obesity-drug-ads-c91de554",{"id":197,"title":198,"source":199,"logo":5,"time":107},1275234,"Novo Nordisk sues Eli Lilly over ‘deliberately false’ weight-loss drug ads","https://www.ft.com/content/812d7feb-34d6-4f0f-8193-b037aee7ec86?syn-25a6b1a6=1",{"id":201,"title":202,"source":203,"logo":19,"time":107},1275239,"Novo Nordisk’s lawsuit against Eli Lilly over ads highlights intense competition in GLP-1 market","https://www.marketwatch.com/story/novo-nordisk-sues-eli-lilly-over-ads-comparing-glp-1-medications-6b223080",{"id":205,"title":206,"source":207,"logo":55,"time":107},1275238,"Weight-loss wars: Why Novo Nordisk is suing Eli Lilly","https://finance.yahoo.com/video/weight-loss-wars-why-novo-nordisk-is-suing-eli-lilly-140102099.html",{"id":209,"title":210,"source":211,"logo":40,"time":107},1275240,"Novo Nordisk is suing Eli Lilly over ads it says mislead consumers on weight loss drug efficacy","https://qz.com/novo-nordisk-sues-eli-lilly-weight-loss-drug-ads-072126",{"id":213,"title":214,"source":215,"logo":5,"time":107},1275244,"Eli Lilly (LLY) Asserts Transparency in Weight Loss Drug Adverti","https://www.gurufocus.com/news/8969287/eli-lilly-lly-asserts-transparency-in-weight-loss-drug-advertisements",{"id":217,"title":218,"source":219,"logo":5,"time":107},1275243,"Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly","https://www.wboc.com/online_features/press_releases/novo-nordisk-takes-action-to-stop-multiple-misleading-national-glp-1-advertising-campaigns-by-eli/article_d51302d4-b88e-52db-afa3-892666e66b36.html",{"id":221,"title":222,"source":223,"logo":5,"time":107},1275242,"Novo Nordisk suing Eli Lilly over GLP-1 'outdated' advertisements","https://www.upi.com/Top_News/World-News/2026/07/21/novo-nordisk-lawsuit-eli-lilly-wegovy-glp-1/1551784642135",{"id":225,"title":226,"source":227,"logo":45,"time":107},1275241,"Novo Nordisk sues Eli Lilly, accusing it of false advertising","https://www.ksl.com/article/51600185/novo-nordisk-sues-eli-lilly-accusing-it-of-false-advertising",{"id":229,"title":230,"source":231,"logo":49,"time":107},1276975,"Novo accuses rival Eli Lilly of \"deceptive\" weight-loss drug ads","https://www.axios.com/2026/07/21/novo-nordisk-eli-lilly-lawsuit",{"id":233,"title":234,"source":235,"logo":57,"time":107},1275248,"Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads (1)","https://news.bloomberglaw.com/litigation/novo-nordisk-says-its-suing-eli-lilly-over-weight-loss-ads",{"id":237,"title":238,"source":239,"logo":68,"time":107},1275247,"Novo sues Lilly over 'pattern of deceptive advertising' in GLP-1 ads","https://firstwordpharma.com/story/7762265",{"id":241,"title":242,"source":243,"logo":76,"time":107},1275246,"Pharmaceutical Giants Clash: Novo Nordisk Takes Legal Action Against Eli Lilly","https://www.devdiscourse.com/article/law-order/3953477-pharmaceutical-giants-clash-novo-nordisk-takes-legal-action-against-eli-lilly",{"id":245,"title":246,"source":247,"logo":75,"time":107},1275245,"Popular Drug Maker Slams GLP-1 Peer on False Advertising","https://www.schaeffersresearch.com/content/news/2026/07/21/popular-drug-maker-slams-glp-1-peer-on-false-advertising",{"id":249,"title":250,"source":251,"logo":26,"time":107},1275249,"Lilly tells Bloomberg ads ‘truthful,’ will defend against Novo suit ‘vigorously’","https://www.tipranks.com/news/the-fly/lilly-tells-bloomberg-ads-truthful-will-defend-against-novo-suit-vigorously-thefly-news",{"id":253,"title":254,"source":255,"logo":5,"time":107},1276976,"GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science","https://www.washingtonpost.com/health/2026/07/21/glp-1-ad-war-leads-lawsuit-by-novo-nordisk-claiming-eli-lilly-misleads",{"id":257,"title":115,"source":258,"logo":17,"time":107},1279727,"https://biz.chosun.com/en/en-science/2026/07/22/4VCKIY7VM5DLJF6OBSWUTNK3NM/",{"id":260,"title":261,"source":262,"logo":70,"time":107},1276977,"Ozempic maker sues US rival over ad campaign","https://www.dw.com/en/ozempic-maker-sues-us-rival-over-ad-campaign/a-78054485",{"id":264,"title":265,"source":266,"logo":24,"time":107},1276978,"Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads","https://www.theguardian.com/business/2026/jul/21/novo-nordisk-eli-lilly-weight-loss-ads",{"id":268,"title":131,"source":269,"logo":5,"time":107},1279729,"https://www.wishtv.com/news/business/novo-nordisk-sues-eli-lilly-alleges-deceptive-advertising-for-zepbound/",{"id":271,"title":272,"source":273,"logo":27,"time":107},1276979,"Novo Nordisk sues rival Eli Lilly over weight loss drug advertising","https://thehill.com/policy/healthcare/5981384-novo-nordisk-sues-eli-lilly-advertising",{"id":275,"title":276,"source":277,"logo":61,"time":107},1279728,"\"Deceptive Advertising!\" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.","https://www.fool.com/investing/2026/07/21/novo-nordisk-vs-eli-lilly-just-moved-from-the-pharmacy-counter-to-federal-court-heres-what-that-means-for-both-stocks/",{"id":279,"title":280,"source":281,"logo":5,"time":107},1275251,"Novo Nordisk Sues Eli Lilly, Accusing It of False Advertising","https://money.usnews.com/investing/news/articles/2026-07-21/novo-nordisk-says-it-is-suing-eli-lilly-accusing-it-of-false-advertising",{"id":283,"title":284,"source":285,"logo":5,"time":107},1275250,"Novo Nordisk sues rival over obesity drug ads","https://iclg.com/news/novo-nordisk-sues-rival-over-obesity-drug-ads",{"id":287,"title":288,"source":289,"logo":29,"time":107},1275255,"Novo Nordisk sues Eli Lilly over Wegovy vs Zepbound ad claims","https://manufacturingchemist.com/novo-nordisk-sues-eli-lilly-over-wegovy-zepbound",{"id":291,"title":292,"source":293,"logo":15,"time":107},1276983,"Why Novo Nordisk Sued Eli Lilly Over Zepbound, Mounjaro Ads","https://www.pharmaceuticalcommerce.com/view/why-novo-nordisk-sued-eli-lilly-over-zepbound-mounjaro-ads",{"id":295,"title":254,"source":296,"logo":5,"time":107},1279734,"https://www.washingtonpost.com/health/2026/07/21/glp-1-ad-war-leads-lawsuit-by-novo-nordisk-claiming-eli-lilly-misleads/",{"id":298,"title":299,"source":300,"logo":56,"time":107},1275254,"Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns","https://www.thepharmaletter.com/pharma-news/novo-nordisk-sues-lilly-over-misleading-glp-1-advertising-campaigns",{"id":302,"title":303,"source":304,"logo":73,"time":107},1276984,"Eli Lilly Stock And 2 Obesity Drug Shares Worth A Closer Look","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/eli-lilly-stock-and-2-obesity-drug-shares-worth-a-closer-loo",{"id":306,"title":307,"source":308,"logo":52,"time":107},1275253,"Novo sues Lilly over 'misleading' GLP-1 ad campaigning","https://pharmaphorum.com/news/novo-sues-lilly-over-misleading-glp-1-ad-campaigning",{"id":310,"title":311,"source":312,"logo":36,"time":107},1276985,"Novo Nordisk sues Eli Lilly over claims in weight-loss drug ads","https://www.foxbusiness.com/retail/novo-nordisk-sues-eli-lilly-claims-weight-loss-drug-ads",{"id":314,"title":272,"source":315,"logo":27,"time":107},1279736,"https://thehill.com/policy/healthcare/5981384-novo-nordisk-sues-eli-lilly-advertising/",{"id":317,"title":318,"source":319,"logo":5,"time":107},1275252,"Novo sues Lilly after alleged misleading and false advertising campaign","https://www.pharmaceutical-technology.com/news/novo-sues-lilly-after-alleged-misleading-and-false-advertising-campaign",{"id":321,"title":322,"source":323,"logo":48,"time":107},1276986,"Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data","https://www.pharmtech.com/view/novo-nordisk-sues-eli-lilly-over-zepbound-and-mounjaro-ads-alleging-omitted-glp-1-dosing-data",{"id":325,"title":326,"source":327,"logo":62,"time":107},1275259,"Novo Nordisk sues Eli Lilly for misleading marketing","https://medwatch.com/News/Pharma___Biotech/article19488459.ece",{"id":329,"title":226,"source":330,"logo":58,"time":107},1275258,"https://www.tradingview.com/news/reuters.com,2026:newsml_L1N43N0EQ:0-novo-nordisk-sues-eli-lilly-accusing-it-of-false-advertising",{"id":332,"title":333,"source":334,"logo":12,"time":107},1276980,"GLP-1 Maker Sued Over Ads; Vaginal Estrogen; Melinda Gates Talks Perimenopause","https://www.medpagetoday.com/endocrinology/generalendocrinology/122290",{"id":336,"title":142,"source":337,"logo":42,"time":107},1275257,"https://live.euronext.com/en/financial-news/novo-nordisk-says-it-suing-eli-lilly-accusing-it-false-advertising",{"id":339,"title":340,"source":341,"logo":14,"time":107},1276981,"Recon: Novo sues Lilly over weight-loss drug ads; Gilead, Merck say HIV pill keeps HIV suppressed in two Phase 3 trials","https://www.raps.org/resource/recon-novo-sues-lilly-over-weight-loss-drug-ads-gilead-merck-say-hiv-pill-keeps-hiv-suppressed-in-two-phase-3-trials.html",{"id":343,"title":138,"source":344,"logo":66,"time":107},1279732,"https://www.reuters.com/world/novo-nordisk-says-it-is-suing-eli-lilly-accusing-it-false-advertising-2026-07-21/",{"id":346,"title":347,"source":348,"logo":23,"time":107},1275256,"Novo Nordisk takes Eli Lilly to court over 'misleading' weight-loss drug ad | Here's what it said","https://www.livemint.com/companies/news/novo-nordisk-sues-eli-lilly-over-alleged-false-advertising-what-we-know-so-far-11784634899640.html",{"id":350,"title":351,"source":352,"logo":59,"time":107},1276982,"Weight-loss drug maker sues rival over which GLP-1 sheds the most pounds","https://www.the-independent.com/news/world/americas/zepbound-wegovy-glp-1-weight-loss-drug-lawsuit-b3019019.html",{"id":354,"title":105,"source":355,"logo":16,"time":107},1279731,"https://www.healthcaredive.com/news/novo-lilly-lawsuit-obesity-drug-glp1-marketing/825801/",{"id":357,"title":138,"source":358,"logo":5,"time":107},1276987,"https://www.linkedin.com/posts/reuters-legal_novo-sues-lilly-claiming-misleading-ads-activity-7485420354119819264-3Nds",{"id":360,"title":186,"source":361,"logo":5,"time":107},1279738,"https://www.usatoday.com/story/money/2026/07/21/wegovy-maker-novo-sues-rival-eli-lilly-weight-loss-drugs/90985399007/",{"id":363,"title":105,"source":364,"logo":16,"time":107},1276988,"https://www.biopharmadive.com/news/novo-lilly-lawsuit-obesity-drug-glp1-marketing/825772",{"id":366,"title":367,"source":368,"logo":5,"time":107},1279737,"What we know of weight-loss drugs’ pricing, availability as Novo sues Lilly","https://www.tradingview.com/news/reuters.com,2026:newsml_L4N43N1CD:0-what-we-know-of-weight-loss-drugs-pricing-availability-as-novo-sues-lilly/",{"id":370,"title":371,"source":372,"logo":5,"time":107},1276989,"Novo Sues Lilly For Allegedly False GLP-1 Advertising 07/22/2026","https://www.mediapost.com/publications/article/416689/novo-sues-lilly-for-allegedly-false-glp-1-advertis.html?edition=143270",{"id":374,"title":318,"source":375,"logo":5,"time":107},1279739,"https://www.pharmaceutical-technology.com/news/novo-sues-lilly-after-alleged-misleading-and-false-advertising-campaign/",{"id":377,"title":378,"source":379,"logo":53,"time":107},1275262,"Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads","https://stocktwits.com/news-articles/markets/equity/novo-nordisk-lawsuit-against-eli-lilly-wegovy-maker-alleges-misleading-zepbound-mounjaro-ads/cZZSBtpR7vE",{"id":381,"title":382,"source":383,"logo":5,"time":107},1275261,"Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising","https://www.benzinga.com/news/health-care/26/07/60580650/novo-nordisk-eli-lilly-weight-loss-drug-advertising-lawsuit",{"id":385,"title":386,"source":387,"logo":5,"time":107},1275260,"Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud","https://www.investing.com/news/stock-market-news/novo-nordisk-sues-eli-lilly-in-highstakes-glp1-advertising-feud-4802957",{"id":389,"title":390,"source":391,"logo":35,"time":107},1275266,"Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising","https://www.barrons.com/articles/novo-nordisk-sues-eli-lilly-weight-loss-drug-advertising-26cc93a4",{"id":393,"title":394,"source":395,"logo":63,"time":107},1276994,"When Does Data Expire? A Novo Nordisk Lawsuit Against Eli Lilly Is About to Find Out","https://www.inc.com/georgia-fearn/novo-nordisk-lawsuit-eli-lilly-data-expiration/91377545",{"id":397,"title":398,"source":399,"logo":43,"time":400},1275265,"Watch Novo Sues Rival Lilly Over Weight-Loss Ads (Correct)","https://www.bloomberg.com/news/videos/2026-07-21/novo-sues-rival-lilly-over-weight-loss-ads-video","3D AGO",{"id":402,"title":138,"source":403,"logo":47,"time":107},1276995,"https://finance.yahoo.com/video/novo-sues-lilly-claiming-misleading-185650805.html",{"id":405,"title":406,"source":407,"logo":10,"time":107},1275264,"Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’","https://www.statnews.com/pharmalot/2026/07/21/novo-nordisk-sues-eli-lilly-glp1-drug-ads",{"id":409,"title":367,"source":410,"logo":44,"time":107},1276996,"https://www.reuters.com/business/healthcare-pharmaceuticals/pricing-availability-novo-lillys-weight-loss-drugs-2026-07-21",{"id":412,"title":413,"source":414,"logo":41,"time":107},1275263,"Novo Nordisk sues Eli Lilly over GLP-1 ads (NVO:NYSE)","https://seekingalpha.com/news/4615863-novo-nordisk-sues-eli-lilly-glp-1-ads",{"id":416,"title":276,"source":417,"logo":61,"time":107},1276997,"https://www.fool.com/investing/2026/07/21/novo-nordisk-vs-eli-lilly-just-moved-from-the-pharmacy-counter-to-federal-court-heres-what-that-means-for-both-stocks",{"id":419,"title":420,"source":421,"logo":32,"time":107},1276990,"Novo Nordisk sues Eli Lilly over ‘misleading’ Zepbound and Mounjaro ads","https://www.prweek.com/article/1965265/novo-nordisk-sues-eli-lilly-misleading-zepbound-mounjaro-ads",{"id":423,"title":424,"source":425,"logo":5,"time":107},1275269,"Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising By Reuters","https://www.investing.com/news/stock-market-news/novo-nordisk-says-it-is-suing-eli-lilly-accusing-it-of-false-advertising-4802984",{"id":427,"title":428,"source":429,"logo":34,"time":107},1276991,"Novo Nordisk sues Eli Lilly for misleading GLP-1 advertising","https://biostock.se/en/2026/07/novo-nordisk-stammer-eli-lilly-for-vilseledande-glp-1-reklam",{"id":431,"title":158,"source":432,"logo":22,"time":107},1279740,"https://www.cbsnews.com/news/novo-nordisk-eli-lilly-false-advertising-lawsuit/",{"id":434,"title":435,"source":436,"logo":69,"time":107},1275268,"Weight-Loss Wars Latest: Novo Nordisk Sues Eli Lilly","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-07-21-2026/card/weight-loss-wars-latest-novo-nordisk-sues-eli-lilly-VA6ZbMWoDwpHUxSruk8s",{"id":438,"title":439,"source":440,"logo":72,"time":107},1276992,"Pharma heavyweights clash over anti-obesity drug ads","https://finance.yahoo.com/healthcare/articles/pharma-heavyweights-clash-over-anti-125954178.html",{"id":442,"title":190,"source":443,"logo":67,"time":107},1275267,"https://www.yahoo.com/news/videos/novo-nordisk-sues-eli-lilly-121736244.html",{"id":445,"title":446,"source":447,"logo":21,"time":107},1276993,"Ozempic-maker Novo Nordisk accuses rival Eli Lilly of false advertising","https://www.bbc.co.uk/news/articles/c3v0rzd2l17o",{"id":449,"title":450,"source":451,"logo":28,"time":107},1276998,"Novo Nordisk: Eli Lilly Is Lying in Weight-Loss Ads","https://www.newser.com/story/393228/novo-nordisk-eli-lilly-is-lying-in-weight-loss-ads.html",{"id":453,"title":454,"source":455,"logo":51,"time":107},1275273,"Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims","https://ca.finance.yahoo.com/news/novo-nordisk-sues-eli-lilly-151800151.html",{"id":457,"title":138,"source":458,"logo":42,"time":107},1275272,"https://live.euronext.com/en/financial-news/novo-sues-lilly-claiming-misleading-ads-weight-loss-drug-battle",{"id":460,"title":454,"source":461,"logo":5,"time":107},1275271,"https://www.proactiveinvestors.co.uk/companies/news/1095788/novo-nordisk-sues-eli-lilly-over-glp-1-drug-advertising-claims-1095788.html",{"id":463,"title":464,"source":465,"logo":54,"time":107},1275270,"Eli Lilly (LLY) Hit with Lawsuit by Rival Novo Nordisk Over Weight-Loss Drug Ads","https://www.tipranks.com/news/eli-lilly-lly-hit-with-lawsuit-by-rival-novo-nordisk-over-weight-loss-drug-ads",{"id":467,"title":468,"source":469,"logo":39,"time":107},1278666,"Wegovy vs. Mounjaro: Lawsuit in the U.S. Over Mounjaro’s Alleged False Advertising","https://www.asiae.co.kr/en/article/world-general/2026072209384272010",{"id":471,"title":367,"source":472,"logo":5,"time":107},1278667,"https://www.tradingview.com/news/reuters.com,2026:newsml_L4N43N1CD:0-what-we-know-of-weight-loss-drugs-pricing-availability-as-novo-sues-lilly",{"id":474,"title":454,"source":475,"logo":5,"time":107},1275275,"https://www.proactiveinvestors.com/companies/news/1095788/novo-nordisk-sues-eli-lilly-over-glp-1-drug-advertising-claims-1095788.html",{"id":477,"title":478,"source":479,"logo":5,"time":107},1278668,"Novo's False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry","https://www.law360.com/healthcare-authority/policy-compliance/articles/2503690/novo-s-false-ad-suit-against-eli-lilly-ramps-up-glp-1-rivalry-",{"id":481,"title":482,"source":483,"logo":58,"time":107},1275274,"Eli Lilly On Novo Nordisk Lawsuit Says \"We Stand Firmly Behind Our Advertising\"","https://www.tradingview.com/news/reuters.com,2026:newsml_FWN43N0R0:0-eli-lilly-on-novo-nordisk-lawsuit-says-we-stand-firmly-behind-our-advertising",{"id":485,"title":486,"source":487,"logo":71,"time":107},1278669,"Pharma Heavyweights Clash Over Anti-Obesity Drug Ads","https://menafn.com/1111425762/Pharma-Heavyweights-Clash-Over-Anti-Obesity-Drug-Ads",{"id":489,"title":490,"source":491,"logo":64,"time":107},1278665,"GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk","https://finance.yahoo.com/healthcare/articles/glp-1-titans-clash-comparing-141700779.html","#8613afff","#8613af4d",1784903477671]